Zyla Life Sciences Deferred Tax Assets, Valuation Allowance
Zyla Life Sciences had Deferred Tax Assets, Valuation Allowance of $93.76 million as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2020-03-26
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $93.76M.
- 2018-12-31: Deferred Tax Assets, Valuation Allowance $80.39M.
- 2017-12-31: Deferred Tax Assets, Valuation Allowance $60.97M.
- 2016-12-31: Deferred Tax Assets, Valuation Allowance $53.66M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2019-12-31 | $93.76M 10-K · filed 2020-03-26 |
| 2018-12-31 | $80.39M 10-K · filed 2020-03-26 |
| 2017-12-31 | $60.97M 10-K · filed 2019-03-29 |
| 2016-12-31 | $53.66M 10-K · filed 2018-03-16 |
| 2015-12-31 | $25.77M 10-K · filed 2017-03-13 |
| 2014-12-31 | $14.02M 10-K · filed 2016-03-11 |
| 2013-12-31 | $5.22M 10-K · filed 2015-03-16 |